B O O K - American College of Rheumatology

B202
Synovial Fluid Analysis and Crystal Identification
(226)
Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic
Foundation; Cleveland, OH
Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical
Center; Blue Bell, PA
Gilda M. Clayburne, MLT; Veterans Affairs Medical Center;
Philadelphia, PA
Upon completion of this session, participants should be able to:
• prepare synovial fluid samples for microscopic examination
• identify various components of synovial fluid
• identify crystals in synovial fluid
Session Overview:
Citrullination is an important post-translational protein
modification, but citrullinated peptides may be the target of
autoantibodies in many individuals with rheumatoid arthritis.
The presence of anti-cyclic citrullinated peptide antibodies in the
serum is a harbinger of likely future development of rheumatoid
arthritis, and often precedes disease onset by years.
Upon completion of this session, participants should be able to:
• describe protein citrullination
• explain the genetic susceptibility loci which may influence
citrullination in rheumatoid arthritis, including the PADI4 locus
• explain how abnormalities in citrullination may trigger an
aberrant immune response in rheumatoid arthritis
tuesday
68
Exhibit Hall Afternoon SnACk
Break
2:00 - 3:00 PM
InnoVAtion Theater
2:00 - 2:45 PM
Halls A1 & A2 (Booth #555)
The following non-CME activity has been planned and will be
implemented in accordance with the requirements of the FDA
and applicable standards of the PhRMA Code on Interactions
with Healthcare Professionals by Actelion Pharmaceuticals US,
Inc. Please visit the Actelion Pharmaceuticals US, Inc. exhibit
booth for more information or see page 292. Seating and light
refreshments are subject to availability.
Clinical Perils in Rheumatology: Uncovering
Pulmonary Arterial Hypertension in Your High-Risk
Patient Populations—The Importance of Aggressive
Screening and Early Diagnosis
ACR Basic Science Symposium
2:30 - 4:00 PM
B313
The Biology of Citrullination R
Moderators: Alisa E. Koch, MD; Unversity of Michigan; Ann
Arbor, MI
Thomas W.J. Huizinga, MD; Leiden University Medical Centre;
Leiden, Netherlands
2:30 PM
Biology of Protein Citrullination
Ger Pruijn, PhD; Radboud University Nijmegen; Nijmegen,
Netherlands
3:00 PM
Experimental Arthritis and Anti-CCP
V. Michael Holers, MD; University of Colorado School of
Medicine; Aurora, CO
3:30 PM
Peptidylarginine Deiminases and the Relationship to
Citrullination in Rheumatoid Arthritis
Guy B. Serre, MD, PhD; University of Toulouse; Toulouse, France
2010 Program Book
ACR Clinical Symposia
2:30 - 4:00 PM
A404
Autologous Stem Cell Transplantation in Pediatric
Rheumatology: Indications and Associated Morbidity
P PS
Moderators: Alexei A. Grom, MD; Children’s Hospital Medical
Center; Cincinnati, OH
B. Anne Eberhard, MB; Schneider Children’s Hospital; New Hyde
Park, NY
2:30 PM
Rationale for the Use of Autologous Stem Cell Transplantation
in Childhood Rheumatic Diseases
Lucy R. Wedderburn, MD, PhD; University College London;
London, United Kingdom
3:00 PM
Review of Existing Protocols and Safety Data in Pediatric Stem
Cell Transplantation
Lisa Filipovich, MD; Cincinnati Children’s Medical Center;
Cinncinatti, OH
3:30 PM
Update on the Autologous Stem Cell Transplantation
Experience in Pediatric Rheumatic Diseases
Nico M. Wulffraat, MD; University Medical Center Utrecht;
Utrecht, Netherlands
Session Overview:
In pediatric rheumatology, autologous stem cell transplantation
has been used in patients with systemic rheumatologic
conditions refractory to more conventional treatments. The
outcome studies show variable results that depend on the
conditioning regimens and the specific underlying rheumatic
disease. The identification of patients who might benefit from
autologous stem cell transplantation is difficult, in part due
to the fact that many pediatric rheumatologists have limited
understanding of the risk/benefit ratio for the procedure.
Upon completion of this session, participants should be able to:
• review the clinical rationale for the use of autologous stem
cell transplantation in pediatric rheumatic diseases
• identify patients for whom autologous stem cell
transplantation might be an appropriate therapy
• describe potential morbidity and mortality of autologous stem
cell transplantation